SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-02-12
Accession Number: 0001493152-26-006407
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226006407/forms-1.htm

Chunk 78 of 83
Word Count: 1485
Character Count: 9435

Document Content:

– Segments: The Company operates in one reportable segment, which is the development of a new product to treat heart failure. The Company’s chief operating decision maker (“CODM”) is the chief executive officer. The CODM regularly reviews and uses consolidated net loss, as reported on our Consolidated Statements of Operations in evaluating the overall performance of our single reporting segment. As a result, the Company has determined that it has only one reportable segment. Although the Company has generated minimal revenue during the reporting period, it continues to incur expenses related to research and development, general and administrative activities, and other operational costs. The CODM uses these expense categories to assess the Company’s performance and allocate resources. The accounting policies of the single segment are the same as those described in the summary of significant accounting policies. There have been no significant changes in measurement methods during the reporting period.

Geographically,
we have no assets in a foreign country requiring separate disclosure.

The
following table provides the significant expenses that management used to manage our one reportable segment:

Research and development $	1,173,645 $	589,951

Selling, general and administrative 5,096,785 2,972,565

Total operating expenses $	6,270,430 $	3,562,516

Note
14 – Subsequent events:

preparing the financial statements, the Company has evaluated all subsequent events and transactions for potential recognition or disclosure
through the date of the of the Report of Independent Registered Accounting Firm, the date the financial statements were available for
issuance.

January 2026, the Company issued 90,000 restricted stock awards to the three independent members of the Company’s
board of directors, which will vest monthly through December 2027.

January 2026, the Company sold $717,523 of Series A-1 Secured Convertible Notes.

Through
and including              , 2026 (the 25th day after
the date of this prospectus) all dealers that effect transactions in these securities, whether or not participating in the listing, may
be required to deliver a prospectus. This is in addition to a dealer’s obligation to deliver a prospectus when acting as an underwriter
and with respect to an unsold allotment or subscription.

Shares

Common
Stock

BIOVENTRIX,
INC.

PROSPECTUS

BENCHMARK,
A STONEX COMPANY

PART
II — INFORMATION NOT REQUIRED IN PROSPECTUS

Item
13. Other Expenses of Issuance and Distribution

The
following table sets forth an itemized statement of the amounts of all our expenses (excluding underwriting discounts and non-accountable
expense allowance) in connection with the registration of the common stock offered hereby. With the exception of the SEC registration
fee, the FINRA filing fee and the Nasdaq initial listing fee, the amounts set forth below are estimates.

SEC registration fee $	2,502

FINRA filing fee 2,750

Nasdaq initial listing fee 50,000

Transfer agent fees 5,000

Accounting fees and expenses [●]

Legal fees and expenses [●]

Printing and engraving expenses 30,000

Other expenses [●]

Total $	[●]

Item
14. Indemnification of Directors and Officers

Section
145 of the Delaware General Corporation Law provides that a corporation may indemnify directors and officers as well as other employees
and individuals against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably
incurred by such person in connection with any threatened, pending or completed actions, suits or proceedings in which such person is
made a party by reason of such person being or having been a director, officer, employee or agent of the corporation. Section 145 of
the Delaware General Corporation Law also provides that expenses (including attorneys’ fees) incurred by a director or officer
in defending an action may be paid by a corporation in advance of the final disposition of an action if the director or officer undertakes
to repay the advanced amounts if it is determined such person is not entitled to be indemnified by the corporation. The Delaware General
Corporation Law provides that Section 145 is not exclusive of other rights to which those seeking indemnification may be entitled under
any bylaw, agreement, vote of stockholders or disinterested directors or otherwise. Our amended and restated bylaws, which will be in
effect upon the consummation of this offering, provide that, to the fullest extent permitted by law, we shall indemnify and hold harmless
any person who was or is made or is threatened to be made a party or is otherwise involved in any threatened, pending or completed action,
suit or proceeding, whether civil, criminal, administrative or investigative by reason of the fact that such person, or the person for
whom he is the legally representative, is or was a director or officer of ours, against all liabilities, losses, expenses (including
attorney’s fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection
with such proceeding.

The
Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director or officer of the
corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as
a director, except for liability of (i) a director or officer for any breach of his or her duty of loyalty to the corporation or its
stockholders, (ii) a director or officer for acts or omissions not in good faith or which involve intentional misconduct or a knowing
violation of law, (iii) a director for unlawful payments of dividends or unlawful stock repurchases, redemptions or other distributions,
(iv) a director or officer for any transaction from which he or she derived an improper personal benefit, or (v) an officer in any action
by or in the right of the corporation. Our amended and restated certificate of incorporation includes this provision.

Additionally,
our fourth amended and restated certificate of incorporation provides that we shall, to the maximum extent permitted from time to time
under the law of the State of Delaware, indemnify and upon request shall advance expenses to any person who is or was a party or is threatened
to be made a party to any threatened, pending or completed action, suit, proceeding or claim, whether civil, criminal, administrative
or investigative, by reason of the fact that such person is or was or has agreed to be a director or officer of ours or while a director
or officer is or was serving at our request as a director, officer, partner, trustee, employee or agent of any corporation, partnership,
joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys’
fees and expenses), judgments, fines, penalties and amounts paid in settlement incurred in connection with the investigation, preparation
to defend or defense of such action, suit, proceeding or claim; provided, however, that the foregoing shall not require us to indemnify
or advance expenses to any person in connection with any action, suit, proceeding or claim initiated by or on behalf of such person or
any counterclaim against us initiated by or on behalf of such person. Such indemnification shall not be exclusive of other indemnification
rights arising under any by-law, agreement, vote of directors or stockholders or otherwise and shall inure to the benefit of the heirs
and legal representatives of such person. Any person seeking indemnification shall be deemed to have met the standard of conduct required
for such indemnification unless the contrary shall be established. Any repeal or modification of our amended and restated certificate
of incorporation shall not adversely affect any right or protection of a director or officer of ours with respect to any acts or omissions
of such director or officer occurring prior to such repeal or modification.

Expenses
incurred by such a person in defending a civil or criminal action, suit or proceeding by reason of the fact that such person is or was,
or has agreed to become, a director or officer of ours, or is or was serving, or has agreed to serve, at our request, as a director,
officer or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, including
any employee benefit plan, or by reason of any action alleged to have been taken or omitted in such capacity shall be paid by us in advance
of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such person to repay such
amount if it shall ultimately be determined that he is not entitled to be indemnified by us as authorized by relevant sections of the
Delaware General Corporation Law. Notwithstanding the foregoing, we shall not be required to advance such expenses to a person who is
a party to an action, suit or proceeding brought by us and approved by a majority of our Board of Directors that alleges willful misappropriation
of corporate assets by such person, disclosure of confidential information in violation of such person’s fiduciary or contractual
obligations to us or any other willful and deliberate breach in bad faith of such person’s duty to us or our stockholders.